Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraperitoneal Paclitaxel in Metastatic Appendiceal Adenocarcinoma
NCT06207305Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2024
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of paclitaxel in appendiceal adenocarcinoma, sponsored by University of Texas MD Anderson Cancer Center. Started Jan 2024; status: recruiting.
02
Drugs
paclitaxel
03
Conditions
appendiceal adenocarcinoma
Beyond the preview
Go deeper on NCT06207305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06207305.